MITOCHONDRIAL MANIPULATION AND ANALYSIS IN DROSOPHILA HEARTS
MITOCHONDRIAL MANIPULATION AND ANALYSIS IN DROSOPHILA HEARTS
批准号:
8190154
负责人:
Gerald W. Dorn
金额:
$22.8万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-01 至 2013-04-30
关键词:
AblationAddressAdultAnimal ModelBiological ModelsBiologyCalciumCalcium SignalingCardiacCardiac MyocytesCardiomyopathiesCardiovascular PhysiologyCellsCellular biologyChimeric ProteinsCommunitiesComplementCultured CellsDataDefectDimensionsDisputesDrosophila genusDrosophila melanogasterFluorescent ProbesFunctional disorderFutureGene MutationGenesGeneticGenetic ModelsHealthHeartHeart DiseasesHeart HypertrophyHeart failureHourHumanHydrogen PeroxideImaging TechniquesIndividualKnockout MiceLaboratoriesLibrariesLifeMammalsMeasuresMediatingMembrane FusionMitochondriaModelingMusMyocardialNeonatalOrganismOxidation-ReductionPhenotypePhysiologyProductionProteinsPublishingRNAReagentReporterResearchResourcesRoleSignal TransductionStructureSystemTechniquesTemperatureTestingTimeTransfectionTransgenic OrganismsTubebaseflygenetic manipulationin vivoinnovationmitochondrial permeability transition poremorphometrymouse modelmutantnoveloverexpressionplanetary Atmospherepromotersmall hairpin RNAtool
中文摘要
描述(由申请人提供):线粒体融合在心肌细胞中的作用存在争议;一些人认为融合在线粒体接触受到物理限制的细胞中没有作用,一些人认为这完全是病理性的,因为它促进sr -线粒体钙运输,打开线粒体通透性过渡孔,还有一些人认为线粒体融合对线粒体健康至关重要。目前还没有发表的体内数据解决这个问题,未发表的小鼠基因敲除结果也不一致。在这个修订的R21中,我们提出了将使用线粒体外膜和内膜融合蛋白的体内遗传操作来确定线粒体融合在果蝇心管中的作用的研究。我们将使用新的果蝇(果蝇)心肌病模型和荧光蛋白指标模型,结合心脏基因操作、心脏表型和活心肌细胞研究。我们将使用遗传互补,用人类有丝分裂蛋白代替被抑制的果蝇线粒体融合蛋白,来探究哺乳动物线粒体融合蛋白的作用。果蝇的心管(在细胞、转录和功能水平上)与哺乳动物的心脏非常相似,可以使用类似的表型技术分析心脏的结构和功能,从而将这种互补/拯救数据外推到更高的生物体中。因为存活的果蝇心管可以在室温和正常气氛下维持数小时,所以它们是活体心肌细胞研究的最佳选择。这种机械细胞生物学和完整心脏生理学的结合在哺乳动物系统中是不可能的。拟议的研究不会解决一个重要的未解科学问题,但将为科学界产生新的试剂和技术,这些试剂和技术将广泛推进使用果蝇平台的心脏研究。事实上,目前的研究是对果蝇心脏系统假设检验研究能力的一次雄心勃勃的测试。我们的具体目标是:SA#1。生成具有心脏特异性线粒体融合缺陷的新型果蝇遗传模型,类似于我们和其他人正在开发的心脏特异性线粒体融合蛋白缺失小鼠模型。SA # 2。开发和部署创新技术,以小鼠模型无法实现的方式,通过使用新型果蝇系表达心肌细胞钙信号,线粒体和肌浆网状形态测定和相互作用,ATP/ADP比率,ROS(过氧化氢)产生和线粒体氧化还原电位的遗传编码荧光探针来分析产生的心脏表型。
英文摘要
DESCRIPTION (provided by applicant): The role of mitochondrial fusion is disputed in cardiac myocytes; some believe fusion has no role in these cells where mitochondrial contact is enforced by physical constraints, some believe it is strictly pathological because it promotes SR-mitochondrial calcium transport that opens mitochondrial permeability transition pores, and some contest that mitochondrial fusion is essential to mitochondrial health. There are currently no published in vivo data addressing this issue and unpublished results using mouse knockouts are inconsistent. In this revised R21 we propose studies that will use in vivo genetic manipulation of mitochondrial outer and inner membrane fusion proteins to define the role of mitochondrial fusion in Drosophila heart tubes. We will use a combination of cardiac gene manipulation, cardiac phenotyping, and live cardiomyocyte research using new Drosophila melanogaster (fruit fly) cardiomyopathy models and fluorescent protein indicator models that we have generated. We will use genetic complementation, substituting human mitofusins for suppressed Drosophila mitochondrial fusion protein, to interrogate the roles of mammalian mitochondrial fusion proteins. The Drosophila heart tube is (at the cellular, transcriptional, and functional level) sufficiently like the mammalian heart to permit analysis of cardiac structure and function using analogous phenotyping techniques, permitting extrapolation of such complementation/rescue data to higher organisms. Because viable Drosophila heart tubes can be maintained for many hours at room temperature and normal atmosphere, they are optimal for live cardiomyocyte studies. This combination of mechanistic cell biology and intact cardiac physiology is not possible in mammalian systems. The proposed studies will not address an important unanswered scientific question, but will generate new reagents and techniques for the scientific community that will broadly advance cardiac studies using the Drosophila platform. Indeed, the current studies are an ambitious test of the capabilities of hypothesis testing research in the Drosophila cardiac system. Our Specific Aims are: SA#1. Generate novel Drosophila genetic models with cardiac-specific mitochondrial fusion defects analogous to the cardiac-specific mitofusin null mouse models we and others are developing. SA#2. Develop and deploy innovative techniques for analysis of resulting cardiac phenotypes in ways not possible with mouse models through the use of novel fly lines expressing genetically-encoded fluorescent probes for cardiomyocyte calcium signaling, mitochondrial and sarcoplasmic reticular morphometry and interactions, ATP/ADP ratio, ROS (hydrogen peroxide) production, and mitochondrial redox potential.
PUBLIC HEALTH RELEVANCE: These studies will begin to answer important fundamental questions about the role of mitochondrial fusion and mitochondrial-sarcoplasmic tethering on in vivo cardiac function. The models, techniques and approaches described herein will be applicable to any future genetic cardiomyocyte-specific manipulations in Drosophila melanogaster, and will establish a useful new high-throughput analytical platform for studies requiring cardiac- specific gene manipulation and phenotyping.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mitofusin Agonists to Treat Neurodegenerative Disease
-
批准号:10383118
-
项目类别:
-
资助金额:$96.87万
-
财政年份:2022
-
负责人:Gerald W. Dorn
-
依托单位:
Mitofusin Agonists to Treat Neurodegenerative Disease
-
批准号:10618385
-
项目类别:
-
资助金额:$98.62万
-
财政年份:2022
-
负责人:Gerald W. Dorn
-
依托单位:
MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE
-
批准号:10290982
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2021
-
负责人:Gerald W. Dorn
-
依托单位:
MITOFUSIN AGONISTS TO TREAT NEURODEGENERATIVE DISEASE
-
批准号:10020801
-
项目类别:
-
资助金额:$22.47万
-
财政年份:2019
-
负责人:Gerald W. Dorn
-
依托单位:
Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A
-
批准号:10471364
-
项目类别:
-
资助金额:$90.18万
-
财政年份:2019
-
负责人:Gerald W. Dorn
-
依托单位:
Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A
-
批准号:9901962
-
项目类别:
-
资助金额:$25.44万
-
财政年份:2019
-
负责人:Gerald W. Dorn
-
依托单位:
Mitofusin agonists to prevent Charcot-Marie-Tooth disease 2A
-
批准号:10253340
-
项目类别:
-
资助金额:$105.92万
-
财政年份:2019
-
负责人:Gerald W. Dorn
-
依托单位:
THE MITOCHONDRIAL DYNAMISM/FITNESS/BIOGENESIS INTERACTOME IN CARDIAC DISEASE
-
批准号:10530619
-
项目类别:
-
资助金额:$91.5万
-
财政年份:2017
-
负责人:Gerald W. Dorn
-
依托单位:
THE MITOCHONDRIAL DYNAMISM/FITNESS/BIOGENESIS INTERACTOME IN CARDIAC DISEASE
-
批准号:10321894
-
项目类别:
-
资助金额:$91.5万
-
财政年份:2017
-
负责人:Gerald W. Dorn
-
依托单位:
MOLECULAR ORCHESTRATION OF MITOCHONDRIAL FITNESS VIA REPLACEMENT OR REPAIR
-
批准号:9101442
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2016
-
负责人:Gerald W. Dorn
-
依托单位:
Linking cell death and mitochondrial quality control mechanisms in heart disease
-
批准号:9032529
-
项目类别:
-
资助金额:$51.5万
-
财政年份:2015
-
负责人:Gerald W. Dorn
-
依托单位:
Linking cell death and mitochondrial quality control mechanisms in heart disease
-
批准号:9172493
-
项目类别:
-
资助金额:$26.8万
-
财政年份:2015
-
负责人:Gerald W. Dorn
-
依托单位:
Linking cell death and mitochondrial quality control mechanisms in heart disease
-
批准号:9223745
-
项目类别:
-
资助金额:$51.06万
-
财政年份:2015
-
负责人:Gerald W. Dorn
-
依托单位:
MICRORNA TARGETING IN HEART FAILURE
-
批准号:8238967
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2011
-
负责人:Gerald W. Dorn
-
依托单位:
MICRORNA TARGETING IN HEART FAILURE
-
批准号:8774629
-
项目类别:
-
资助金额:$37.43万
-
财政年份:2011
-
负责人:Gerald W. Dorn
-
依托单位:
MITOCHONDRIAL MANIPULATION AND ANALYSIS IN DROSOPHILA HEARTS
-
批准号:8309022
-
项目类别:
-
资助金额:$19.0万
-
财政年份:2011
-
负责人:Gerald W. Dorn
-
依托单位:
MICRORNA TARGETING IN HEART FAILURE
-
批准号:8588991
-
项目类别:
-
资助金额:$37.24万
-
财政年份:2011
-
负责人:Gerald W. Dorn
-
依托单位:
MICRORNA TARGETING IN HEART FAILURE
-
批准号:8399037
-
项目类别:
-
资助金额:$36.18万
-
财政年份:2011
-
负责人:Gerald W. Dorn
-
依托单位:
CTRIP: Genetic Testing to Individualize Management of Common Heart Diseases
-
批准号:7853706
-
项目类别:
-
资助金额:$96.11万
-
财政年份:2009
-
负责人:Gerald W. Dorn
-
依托单位:
CTRIP: Genetic Testing to Individualize Management of Common Heart Diseases
-
批准号:7939777
-
项目类别:
-
资助金额:$94.39万
-
财政年份:2009
-
负责人:Gerald W. Dorn
-
依托单位:
海外基金